|
|
|
|
|
WATCHMAN device
|
|
|
AF Is Associated with Serious Events Different Vascular Territories1
|
|
|
Relative Risk Reduction of Stroke in Atrial Fibrillation
|
|
|
Relative Risk Reduction of Stroke in Atrial Fibrillation
|
|
|
Relative Risk Reduction of Stroke in Atrial Fibrillation
|
|
|
AF Investigators’ Collaborative Analysis
|
|
|
CHADS2 score
|
|
|
Dia 12
|
|
|
|
Nieuwe antithrombotica bij boezemfibrilleren
|
|
|
farmacologie
|
|
|
|
|
inclusion
|
|
|
exclusion
|
|
|
|
Dia 21
|
|
|
|
Dia 23
|
|
|
|
conclusions
|
|
|
|
RE-LY: A Non-inferiority Trial
|
|
|
RE-LY primary outcome: stroke or systemic embolism
|
|
|
Stroke or Systemic Embolism
|
|
|
|
|
RELY: Conclusions
|
|
|
Dia 33
|
|
|
Study Design
|
|
|
Primary Efficacy Outcome Stroke and non-CNS Embolism
|
|
|
ROCKET
|
|
|
ROCKET Summary
|
|
|
RE-LY: A Non-inferiority Trial
|
|
|
RE-LY primary outcome: stroke or systemic embolism
|
|
|
Stroke or Systemic Embolism
|
|
|
|
|
|
Event rates in VKA group% per year)
|
|
|
A comparison of risk reductions; point estimates and CI’s
|
|
|
conclusies
|
|
|
problemen
|
|
|
Gezondheidsraad 15 mei 2012
|
|
|
Gezondheidsraad 15 mei 2012
|
|
Deel deze pagina met collega's en vrienden: